Huajin Pharmaceutical is a biomedical technology company dedicated to the treatment of cancer tumors. It is mainly engaged in the research and development of new anti-cancer drugs. It has mastered a series of new biological treatment technologies for malignant tumors, and has patents with corresponding independent intellectual property rights. Recently, it completed the pre-B round of financing at the level of tens of millions of dollars. This round of financing was led by Wenzheng Assets, and also participated by Tongchuan Venture Capital, Xie Nuo Investment, and Huarui Fund. This round of financing will be mainly used for the research and development of original first-in-class oncolytic bacteria products, to promote the development of the world’s first tumor-targeted amino acid metabolic pathway-regulated oncolytic bacterial biological product SGN1, and to accelerate its global clinical pipeline process .
This article is reproduced from: https://www.itjuzi.com/investevent/13235378
This site is for inclusion only, and the copyright belongs to the original author.